Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of August 2026
Principal Executive Office: Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia
Signatory: Julian Babarczy, Chairman (Dated August 17, 2026)
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a disclosure of regulatory matters rather than a financial statement.
Material Changes
No material financial changes versus the prior comparable period are disclosed in this filing. The document focuses on regulatory compliance regarding the Takeovers Panel.
Guidance, Outlook, and Risks
Regulatory Disclosure: The filing includes Exhibit 99.1, titled "Disclosure Under Takeovers Panel GN 20." This indicates a specific regulatory event or disclosure requirement under the Australian Takeovers Panel guidelines.
Registration Statements: This Form 6-K is incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076).
Outlook: The filing text does not provide specific management commentary, financial guidance, or details on risks and contingencies beyond the regulatory disclosure.
Investor Verification Checklist
- Review the content of Exhibit 99.1 to understand the specific nature of the "Disclosure Under Takeovers Panel GN 20."
- Verify the impact of this disclosure on the referenced Form S-8 and Form F-3 registration statements.
- Confirm the company's status as a "development stage enterprise" and its current cash runway, as no financial data is present in this specific filing.
- Check for subsequent filings that may provide financial details related to the August 2026 period.